Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALA for Visualization of Primary Glial Neoplasms
NCT00961090Phase 2Completed
- Sponsor
- Matthew R Quigley
- Start
- Sep 2009
- Primary completion
- Apr 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of 5-aminolevulinic acid in glioblastoma (GBM) and malignant glioma, sponsored by Matthew R Quigley. Primary endpoint: More complete resection of malignant brain tumors. Started Sep 2009; status: completed.
02
Drugs
5-aminolevulinic acid
03
Conditions
glioblastoma (GBM)malignant glioma
Beyond the preview
Go deeper on NCT00961090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00961090.